This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, New Zealand, Poland, Singapore, South Africa, Spain, Turkey.
The drug PROQUAD contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
MFZ8I7277D - MEASLES VIRUS STRAIN ENDERS' ATTENUATED EDMONSTON LIVE ANTIGEN
|
2
|
UNII
47QB6MX9KU - MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN
|
3
|
UNII
52202H034Z - RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN
|
|
Rubella virus vaccine contains live attenuated rubella virus, produced in human diploid (MRC-5) cells. It is a virus vaccine for active immunization against rubella that is subcutaneously administered. |
|
4
|
UNII
GPV39ZGD8C - VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN
|
|
Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J07BD54 | Measles, combinations with mumps, rubella and varicella, live attenuated | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BD Measles vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 525517080020004 |
| CA | Health Products and Food Branch | 02399229 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 52-MBE-0416 |
| EE | Ravimiamet | 1243628, 1243639, 1243640, 1243651, 1243662 |
| ES | Centro de información online de medicamentos de la AEMPS | 05323010 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 117303 |
| HK | Department of Health Drug Office | 54831 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 7893 |
| IT | Agenzia del Farmaco | 036893016, 036893028, 036893030, 036893042, 036893055, 036893067, 036893079, 036893081, 036893093, 036893105, 036893117, 036893129, 036893131 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1030464, 1030465, 1030466, 1030467, 1030468, 1030469, 1030470, 1030471, 1030472, 1030473, 1030474, 1091078, 1091079 |
| NZ | Medicines and Medical Devices Safety Authority | 11900 |
| PL | Rejestru Produktów Leczniczych | 100348562 |
| SG | Health Sciences Authority | 13563P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699636960400 |
| US | FDA, National Drug Code | 0006-4171 |
| ZA | Health Products Regulatory Authority | 49/30.2/1069 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.